Clinical Trials Logo
  1. Home
  2. Endometrial Hyperplasia
  3. NCT05903131

A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

Endometrial Hyperplasia Clinical Trial

Official title:
A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

Clinical Trial Summary

Up to 60% of endometrial cancer cases are attributed to obesity, in part because obesity promotes development of atypical endometrial hyperplasia (AEH), and up to 40% of women with AEH go on to develop endometrial cancer. The increasing prevalence of obesity in premenopausal women has resulted in increasing rates of AEH in this age group. Hysterectomy with removal of the fallopian tubes and ovaries is 100% effective in preventing endometrial cancer, but this approach results in infertility. Fertility-sparing treatments exist, such as treatment with oral or intrauterine progestin, but these treatments do not work uniformly and do not combat the underlying cause of endometrial cancer, which is obesity and metabolic syndrome. Additionally, up to 41% of women on progestin eventually experience relapse of AEH or endometrial cancer. Third, many patients have insulin resistance that may worsen with progestin therapy. Thus, to improve treatment of AEH and grade 1 endometrial cancer, prevent and reverse endometrial cancer, and allow women to preserve their fertility, the investigators must integrate an effective weight loss strategy to be given with progestin treatment. It is the hypothesis that premenopausal women with AEH desire uterine preservation will be more likely to have atypia-free uterine preservation at one year if they receive progestin in combination with a behavioral weight loss intervention versus progestin plus enhanced usual care.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05903131
Study type Interventional
Source Washington University School of Medicine
Contact Andrea R Hagemann, M.D., MSCI
Phone 314-362-1763
Email hagemanna@wustl.edu
Status Not yet recruiting
Phase Phase 2
Start date June 30, 2024
Completion date June 30, 2029
View Details
See also
  Status Clinical Trial Phase
Completed NCT05378152 - Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity N/A
Withdrawn NCT00123175 - Treatment of Endometrial Hyperplasia With an Intrauterine Device (IUD) Phase 1/Phase 2
Completed NCT02100137 - Women With Asymptomatic Endometrial Hyperplasia N/A
Completed NCT00242710 - Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women Phase 3
Not yet recruiting NCT04191603 - TWO DİFFERENT ELECTROSURGERY DEVICES AS MONOPOLAR HOOC AND PLASMAKINETIC BIPOLAR SPATULA EFFECTIVENESS DURING COLPOTOMY N/A
Completed NCT03032848 - Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients Phase 4
Completed NCT00339651 - Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer
Recruiting NCT01234818 - Management of Endometrial Hyperplasia With a LNG-IUS: Multicenter Study: KGOG2006 Phase 2
Recruiting NCT04362046 - Fertility Sparing Management of EndomeTrial Cancer and Hyperplasia N/A
Active, not recruiting NCT05257057 - Frequency of Endometrial Cancer Precursors Associated With Lynch Syndrome
Completed NCT00883662 - Mirena Observational Program N/A
Completed NCT01499602 - Efficacy of LNG-IUS for Treatment of Non-atypical Endometrial Hyperplasia in Perimenopausal Women N/A
Completed NCT01074892 - A Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia Phase 4
Not yet recruiting NCT05829460 - Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia Phase 2
Withdrawn NCT04897217 - Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Management of Atypical Endometrial Hyperplasia Phase 3
Recruiting NCT03176992 - Surgicel® & Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding Phase 2
Not yet recruiting NCT00919919 - Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen Phase 2
Recruiting NCT03207061 - Can 3D Ultrasound be Used as an Alternative to MRI to Assess Myometrial Invasion in Endometrial Cancer? N/A
Recruiting NCT03207126 - Pilot Study: Can Ultrasound Guided Biopsy be Used as an Alternative to Hysteroscopy? N/A
Completed NCT03207074 - Can the iKnife Distinguish Between Normal and Malignant Endometrial Tissue? N/A